NCCN Breast Treatment Guideline Update:
The National Comprehensive Cancer Network recommends olaparib as a preferred single agent for recurrent or metastatic breast cancer and highlights that patients being considered for olaparib are also eligible for germline BRCA1/2 testing.1
- NCCN has recognized olaparib as a new therapeutic option for patients with HER2-negative metastatic breast cancer due to its demonstrated efficacy in the OlympiAD trial.1,2
- They have also recognized the important role that BRCA testing plays in identifying which patients are likely to benefit from olaparib treatment.
- It is therefore critical to know the BRCA status for all of your patients with HER2-negative metastatic breast cancer.
- This is an exciting step forward in expanding the role of precision medicine and improving outcomes for patients with breast cancer.
Bottom Line: The field of genetics and medical management for BRCA mutation carriers is continually evolving. NCCN guidelines are updated annually and in 2017, they have provided additional guidance around treatment options for patients with HER2-negative, BRCA1/2-mutated recurrent or metastatic breast cancer. Additionally, they have expanded the eligibility criteria for BRCA testing to help identify those patients that are likely to benefit from olaparib. Myriad is committed to helping you make tailored management recommendations for your patients based on their genetic status and current medical guidelines.1
- NCCN® Invasive Breast Cancer V3.2017 BINV-O1
- Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533
olaparib is not approved by the FDA for this indication